Parvinder Singh Thiara
Director/Board Member at ZURA BIO LIMITED
Net worth: 1 M $ as of 2024-05-30
Profile
Parvinder Singh Thiara is the founder of Athanor Capital LP, which was founded in 2017.
He holds the title of CIO & Chief Compliance Officer at Athanor Capital LP.
Mr. Thiara's current jobs include being a Director at Tourmaline Sub, Inc. since 2022, an Independent Director at Tourmaline Bio, Inc. since 2023, and an Independent Director at Zura Bio Ltd.
since 2023.
Mr. Thiara's former job was as a Senior Vice President at D.E.
Shaw & Co., Inc. Mr. Thiara's education includes a graduate degree from the University of Oxford and an undergraduate degree from Harvard College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.32% | 2024-06-04 | 82,782 ( 0.32% ) | 1 M $ | 2024-05-30 |
Parvinder Singh Thiara active positions
| Companies | Position | Start |
|---|---|---|
| ZURA BIO LIMITED | Director/Board Member | 2023-05-31 |
Athanor Capital LP
 Athanor Capital LP Investment ManagersFinance Athanor Capital LP (Athanor) is a hedge fund manager headquartered in New York City. The firm was founded by Parvinder S. Thiara in 2017 and is a subsidiary of Athanor Capital GP LLC. Athanor serves as the investment adviser, with discretionary trading authority over private pooled investment vehicles. | Founder | 2016-12-31 |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Director/Board Member | 2022-08-31 |
Former positions of Parvinder Singh Thiara
| Companies | Position | End |
|---|---|---|
D.E. Shaw & Co., Inc.
 D.E. Shaw & Co., Inc. Investment ManagersFinance D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY. | Corporate Officer/Principal | - |
Training of Parvinder Singh Thiara
| University of Oxford | Graduate Degree |
| Harvard College | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ZURA BIO LIMITED | Health Technology |
| Private companies | 3 |
|---|---|
D.E. Shaw & Co., Inc.
D.E. Shaw & Co., Inc. Investment ManagersFinance D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY. | Finance |
Athanor Capital LP
Athanor Capital LP Investment ManagersFinance Athanor Capital LP (Athanor) is a hedge fund manager headquartered in New York City. The firm was founded by Parvinder S. Thiara in 2017 and is a subsidiary of Athanor Capital GP LLC. Athanor serves as the investment adviser, with discretionary trading authority over private pooled investment vehicles. | Finance |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
- Stock Market
- Insiders
- Parvinder Singh Thiara
